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The blood-brain barrier (BBB) is known to protect healthy brain cells from potentially
dangerous chemical agents, but there are many evidences supporting the idea that this
protective action is extended to tumor cells. Since the process of angiogenesis in brain
tumors leads to BBB breakdown, biochemical characteristics of the BBB seem to be
more relevant than physical barriers to protect tumor cells from chemotherapy. In fact, a
number of resistance related factors were already demonstrated to be component of both
BBB and tumor cells. The enzyme glutathione S-transferases (GST) detoxify electrophilic
xenobiotics and endogenous secondary metabolites formed during oxidative stress. A
role has been attributed to GST in the resistance of cancer cells to chemotherapeutic
agents. This study characterized 8-methoxypsoralen (8-MOP) as a human GST P1-1 (hGST
P1-1) inhibitor. To identify and characterize the potential inhibitory activity of 8-MOP, we
studied the enzyme kinetics of the conjugation of 1-chloro-2,4-dinitrobenzene (CDNB)
with GSH catalyzed by hGST P1-1. We report here that 8-MOP competitively inhibited
hGST P1-1 relative to CDNB, but there was an uncompetitive inhibition relative to GSH.
Chromatographic analyses suggest that 8-MOP is not a substrate. Molecular docking
simulations suggest that 8-MOP binds to the active site, but its position prevents the
GSH conjugation. Thus, we conclude that 8-MOP is a promising prototype for new GST
inhibitors pharmacologically useful in the treatment of neurodegenerative disorders and
the resistance of cancer to chemotherapy.
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INTRODUCTION
The Brain Blood Barrier (BBB) protects central nervous system
(CNS) against chemical and biological insults. It was described
as composed mainly of highly specialized endothelial cells with
tight junctions, and astrocyte endfeets with anchoring transmem-
brane proteins (Bentivoglio and Kristensson, 2014). However,
nowadays it is clear that a number of enzymes are also part of
this barrier (Shawahna et al., 2013). The idea that the BBB has
not only a physical constitution, but also a metabolic one, is
not new (Minn et al., 1991; El-Bacha and Minn, 1999), drug-
metabolizing enzymes continues to be identified (Decleves et al.,
2011), and they represent difficulties in drug delivery to the brain
(Bentivoglio and Kristensson, 2014). Therefore, BBB is a crit-
ical obstacle for the pharmacologic treatment of brain tumors
(Jovc´evska et al., 2013), leading to research on BBB-disrupting
strategies for enhanced drug delivery in these cases (Liu et al.,
2014).
Glutathione S-transferases (GST; EC 2.5.1.18), multifunc-
tional enzymes which are mainly involved in phase II metabolism
and antioxidant cell systems (Di Pietro et al., 2010), are among the
drug-metabolizing enzymes present in BBB. It seems that these
GSTs, mainly the GSTP1 (GST-π) isoform, which is the most
abundant at the BBB, protect cells against oxidative stress and
are involved in the phenomenon of drug resistance (Shawahna
et al., 2013). In fact, GSTs promote the conjugation between
drugs and the tripeptide glutathione (GSH), and special attention
has been given to these enzymes since they are strongly asso-
ciated with resistance, remarkable in cancer (Sau et al., 2010).
The most highly expressed GST isoenzyme in various human
cancerous and precancerous tissues is also GST-π (Sau et al.,
2010). Overexpression of this class of GST was associated with
drug resistance or poor prognosis in many kinds of tumors
(Wang et al., 2007, 2011; Pasello et al., 2008; Geng et al., 2013),
including gliomas (Okcu et al., 2004; Calatozzolo et al., 2005),
the most common form of primary brain tumors, and glioblas-
toma (the highest malignant glioma) (Lo et al., 2004), the most
frequent brain tumor in adults (Brennan, 2011). Furthermore,
it was documented that GST-π polymorphisms are associated
with survival in anaplastic glioma patients; an explanation is
that lower activity GST genotypes will allow more prolonged
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exposure of tumor cells to chemotherapeutic agents (Kilburn
et al., 2010).
There are experimental observations suggesting that inhi-
bition of GST increases the response of glioblastoma cells to
alkylating agents better than the inhibition of the enzyme
O6-methylguanine-DNA methyltransferase (MGMT) (Juillerat-
Jeanneret et al., 2008), the most frequently associated fac-
tor to temozolomide resistance in glioblastomas (Mrugala and
Chamberlain, 2008). Therefore, inhibition of Pi-class GST activ-
ity or inhibition of its expression has been shown to increase the
tumor sensitivity to many drugs (Sau et al., 2010). Indeed, many
inhibitors and pro-drugs targeted to GSTs have been developed
for a long time, but the clinical effectiveness of these molecules
is poor and do not justify therapeutic use (Mahajan and Atkins,
2005). The search for effective GST inhibitors for use in cancer
therapy is not recent. Almost two decades ago, clinical studies
indicated ethacrynic acid as a candidate for modulation of drug
resistance (Lacreta et al., 1994). At the same time, the selective
GST-π inhibitor TER-117 was synthesized (Lyttle et al., 1994
include on references), but there are no recent studies with this.
Other GST-π specific inhibitors were able to revert multiple drug
resistance in cholangiocarcinoma (Nakajima et al., 2003).
In this work we presented the 8-MOP, a well-known drug
that has been used for decades in the treatment of skin disease
(Tzaneva et al., 2009), as a novel promising molecule to develop
new GST-π inhibitors, detailing its mechanism of action, and
showing the potential for cancer therapy by using an in vitro
model of glioblastoma.
MATERIALS AND METHODS
ASSAY OF GLUTATHIONE S-TRANSFERASE ACTIVITY
GST activity was measured as previously described (van Haaften
et al., 2001) with modifications. Briefly, the reaction of 1mM
GSH with 1mM 1-chloro-2,4-dinitrobenzene (CDNB) catalyzed
by GST (GSTP1-1 at 0.1U/ml or 0.15mL of human glioma
cells lysate in 100mM potassium phosphate buffer, pH 6.5, at
25◦C) was monitored spectrophotometrically by recording the
increase in absorbance at 340 nm. Absorbance units were con-
verted to concentration of DNP-SG (the conjugate of GSH and
CDNB) as previously described (Mannervik and Guthenberg,
1981). A correction for the spontaneous reaction was made by
monitoring formation of DNP-SG in the absence of enzyme. For
inhibitory effect analysis, increasing concentrations of 8-MOP
(Sigma®) were used. In the test with lysates of glioma cells,
GST activity was expressed as percentage of the control group.
8-MOP was dissolved in DMSO, which was present in all groups
and did not affect the GST activity. The effect of 8-MOP in
spontaneous formation of DNP-SG was also discounted by mon-
itoring the reaction in the presence of the drug and absence of
enzyme. To study the inhibitory mechanism, substrate concen-
trations (CDNB or GSH) were varied (when GSH concentration
was varied, the CDNB concentration was kept at 1mM and vice
FIGURE 1 | (A) Concentration-dependent inhibition of GST-π activity by
8-MOP. Data did not present normal distribution and were analyzed by
Kruskal-Wallis non-parametric test followed by Dunn’s Multiple
Comparison test; ∗p < 0.05 compared to the control group. (B)
Michaelis-Mentem (R2 = 0.9874 without 8-MOP and 0.9545 with 8-MOP)
and (C) Lineweaver-Burk plots showing competitive inhibition of human
GST-π toward CDNB by 8-MOP. The Km and Vmax of the enzyme for
CDNB were 0.30mM (SD = 0.05) and 11.58μmol/min.mg (SD = 0.77),
respectively, but these same values in the presence of 0.1mM 8-MOP
were 0.68mM (SD = 0.06) and 11.71μmol/min.mg (SD = 3.10). (D)
Michaelis-Mentem (R2 = 0.9733 without 8-MOP and 0.9736 with
8-MOP) and (E) Lineweaver-Burk plots showing an uncompetitive
inhibition of human GST-π toward GSH by 8-MOP. The Km and Vmax for
GSH were 0.25mM (SD = 0.08) and 11.36μmol/min.mg (SD = 1.31),
respectively. These values in the presence of 0.1mM 8-MOP were
0.09mM (SD = 0.02) and 4.70μmol/min.mg (SD = 0.21). The enzyme
was used at 0.1U/mL. The graphs are representative of five
independent experiments.
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versa). Five independent experiments were performed with and
without 8-MOP at a concentration near the IC50. Vmax and Km
values were calculated by non-linear regression following the
Michaelis-Mentem mode and the mechanism was visualized by
Lineweaver-Burk plot.
UV-VIS SPECTROPHOTOMETRY AND HIGH PERFORMANCE LIQUID
CHROMATOGRAPHY (HPLC) ANALYSIS
Electronic absorption spectra of solutions containing CDNB
with GSH or 8-MOP with GSH in the presence or absence
of GST-π were recorded using a Hewlett-Packard model 8452
A spectrophotometer in 1 cm quartz cuvettes and compared to
CDNB alone and 8-MOP alone spectra. Chromatographic anal-
yses of CDNB/CDNB-conjugate and 8-MOP/8-MOP-conjugate
were performed according to previous description in literature
(Wang and Jiang, 2006; Vaidya and Gerk, 2007) with modifica-
tions (Supplementary Table S1). A dual wavelength ultraviolet
absorbance detector was used.
IN SILICO APPROACH
A docking study of the 8-MOP in the GST structure (Protein Data
Bank code 3IE3) was conducted. In this structure the enzyme is
complexed with 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol
(NBDHEX) (Federici et al., 2009). The space for molecular dock-
ing was defined based on the location of the NBDHEX, as well
as the amino acids with important interactions. This space con-
sisted of a 14.0 Å sided box, spaced 1 Å grid. The AutoDock
Vina 1.1.2 was used in standard configuration for molecular
docking with 8-MOP. The resulting geometry of each enzyme-
ligand complex was submitted to amolecular dynamic simulation
(MD) using AMBER 10.0 (Case DA, AMBER 10—University of
California, San Francisco, 2008). It was performed a two nanosec-
onds simulation, at 300K, and with the implicit solvent model
described by Hawkins et al. (1996). Separately, protein, 8-MOP,
and the NBDHEX structures were submitted to the same MD
calculation. The binding energies (Ebind) were obtained from the
average potential energies of the structures resulting from theMD
FIGURE 2 | (A) Absorption spectra of CDNB and 8-MOP in the
presence of GSH. (B) Spectrophotometric evidences of DNP-SG,
but not “8-MOP-SG,” in spectra after addition of GST-π. The
maximum absorbance values for the solutions containing
CDNB/GSH/enzyme (250, 340 nm) and 8-MOP/GSH/enzyme (248,
301 nm) were used for HPLC analysis. (C) Chromatographic
detection of DNP-SG (RT = 4.6min.), and (D) no evidences of
“8-MOP-SG.”
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through the equation Ebind = Ecomplex − (EGST + Eligand),
in which Ecomplex, EGST and Eligand correspond to the aver-
age potential energies of the complex ligand-GST, the enzyme
alone and the ligand alone respectively. PyMOL (The Molecular
Graphics System, 2002—DeLano Scientific, San Carlos, CA, USA)
was used for visual interpretation of the results.
CELL CULTURES AND PREPARATION OF CYTOSOLIC PROTEIN EXTRACT
Human glioblastoma GL-15 cells (Bocchini et al., 1991) were cul-
tured at 37◦C in Dulbecco modified Eagle’s medium (DMEM),
supplemented with 1mM pyruvic acid, 2mM L-(+)-glutamine,
44mM NaHCO3, 10% fetal bovine serum, 100 IU/mL penicillin
and 100μg/mL streptomycin in a humidified atmosphere of 5%
CO2 and 95% air. The culture medium was changed every 2 days.
Primary cultures of astrocytes from Wistar rats were performed
according to previous descriptions (Silva et al., 2008) and main-
tained under the same conditions described above. The study
was conducted according to guidelines of the institutional animal
ethics committee (Federal University of Bahia—Brazil). In order
to evaluate the activity of GST from GL-15 cells, confluent cul-
tures in 10mm dishes were lysated with 1mL of distilled water
under vigorous shaking for 30min. The extract was centrifuged
at 5000 g (10min) and the supernatant stored at −70◦C until use
in GST activity assays.
IMMUNOCYTOCHEMISTRY
GST-π expression in GL-15 cells was attested by immunos-
taining with anti-GSTP1-1 antibody. The cells were permeabi-
lized in methanol at −20◦C for 10min and incubated with the
primary antibody (rabbit polyclonal IgG anti GSTP1/2—Santa
Cruz®, 1:500) for 1 h. Subsequently, cells were rinsed three times
with PBS, incubated with the secondary antibody (Conjugated
Alexa Fluor® 546 goat anti-rabbit IgG—Invitrogen®, 1:400) and
finally observed by fluorescence microscopy (Olympus AX70
microscope—green filter). Nuclei were stained by the dye Hoechst
33258 (ex/em 340/510 nm) (Oliveira et al., 2010). For negative
control, cells were incubated with only secondary antibody under
the same conditions described above.
EVALUATION OF INTRACELLULAR REDUCED GLUTATHIONE CONTENT
Monochlorobimane (MCB) assay (Ublacker et al., 1991) was used
to evaluate GSH depletion. After 30min exposure to 8-MOP (0.05
or 0.4mM) and CDNB (0.05mM), GL-15 cells were washed three
times with PBS, incubated with 1mM MCB in medium with 1%
ethanol for 40min, washed again and observed by fluorescence
microscopy (Olympus BX 51—URA2, San Jose, USA). The fluo-
rescence mirror unit Olympus U-MWU2 was selected to observe
cells (ex/em 330–385/420 nm). The exposure time of 60ms was
used in micrographs for all samples.
CELL VIABILITY MEASUREMENT AND MICROSCOPIC ANALYSIS
In order to evaluate the chemosensitizer potential of 8-MOP, cells
were seeded in 96-well plates at a density of 3.1 × 104 cells/cm2,
and cultured for 24 h prior to treatments with increasing con-
centrations of chemotherapeutic drugs for 48 h in the presence
or absence of 0.05mM 8-MOP, which was added 2 h before
treatments. Both drugs and 8-MOP were dissolved in DMSO
(final concentration 0.5% v/v). Cell viability was measured
by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) method (Mosmann, 1983). In short, after treatment
the MTT reagent was added to each well (1mg/mL). Following
additional 2 h incubation, 100μL of 20% SDS was added. The
absorbance was then measured at 595 nm using a microplate
reader (THERMO PLATE, model TP-reader—type B). Wells
without cells were used as blanks. To access cytotoxicity of 8-MOP,
GL-15 cells were treated for 72 h under the same described con-
ditions. Cell growth after long-term (10 days) exposure to a low
dose 8-MOP (0.02mM), added during each medium change, was
evaluated by Trypan blue exclusion assay (Louis and Siegel, 2011)
in cultures at low cell density (3.86 × 103), and expressed as per-
centage of cells in the first day. Changes in cell morphology were
observed by contrast phase microscopy and nuclear morphology
was assessed by Hoechst 33258 staining.
STATISTICS ANALYSES
Data were showed as mean with SEM or median with
range according to their distribution, analyzed by Shapiro-
Wilk normality test and Skewness (normal: < 1 or > −1) and
Kurtosis (normal: < 2 or > −2) calculation. Parametric or non-
parametric statistic tests were also chosen according to the distri-
bution. The most appropriate test for each experiment was used
and this information is in the respective figure legends. At least
three independent experiments were done for each assay.
RESULTS
8-MOP INHIBITS GST-π ACTIVITY
GST activity was concentration dependently inhibited by 8-MOP
(Figure 1A), with the IC50value of 0.092mM (Supplementary
Figure S1A). The enzyme shows a characteristicMichaelisMenten
behavior toward both substrates, but the inhibitor presented a
double behavior. A competitive inhibition pattern was observed
when 0.1mM 8-MOP was incubated with GST- π and varying
concentrations of CDNB (Figures 1B,C). The presence of 8-MOP
Table 1 | Energies from the docking of 8-MOP and NBDHEX.
Complexes AMBER Autodock Vina (Kcal/mol)
Average potential energies (Kcal/mol) Binding energy (Kcal/mol)
Complex Ligand GST
NBDHEX/GST −6131.88 41.73 −6136.48 −37.13 −5.4
8-MOP/GST −6697.87 15.87 −6136.48 −577.26 −6.4
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increased the calculated Km value, but it did not change signifi-
cantly the calculated Vmax value, indicating that both, inhibitor
and substrate (CDNB) bind to the same region of the active site.
However, when 0.1mM 8-MOP was tested varying GSH con-
centrations both Km and Vmax values decreased, which can be
interpreted as an uncompetitive inhibition (Figures 1D,E), indi-
cating that inhibitor and substrate (GSH) bind to different sites
in the enzyme or different regions of the active site.
8-MOP IS NOT A GST-π SUBSTRATE
Since 8-MOP inhibits competitively GST-π activity, we hypoth-
esized that this drug could be a substrate, just as CDNB. If
it was true, a new compound “8-MOP-SG” (Supplementary
Figure S1B) would be formed. UV-Vis spectrophotometric anal-
ysis clearly showed the generation of DNP-SG that has a different
absorption spectrum when compared to CDNB, by addition of
GSH in the presence of GST-π. In contrast, the addition of
enzyme in the solution containing 8-MOP/GSH did not change
its absorption profile, suggesting no alteration in the 8-MOP
structure (Figures 2A,B). To certify that 8-MOP-SG was not
present in the solution, HPLC was carried out using maxi-
mal absorbance values for each solution for detection. Again,
DNP-SG was identified with a retention time (RT) lower than
CDNB (Figure 2C), but a single peak was present in the chro-
matogram for 8-MOP/GSH plus GST-π (Figure 2D). The theo-
retical log P-value for CDNB and log D value for DNP-SG are
2.46 and −3.14, respectively (Supplementary Figure S2), which
justifies the lower RT of DNP-SG. On the other hand, the log
P-value for 8-MOP is 1.78 and the theoretical log D value for
the proposed 8-MOP-SG is −2.58, but no peak in a very low RT
FIGURE 3 | (A) Interactions between 8-MOP (white) and GST after
2 ns simulation. The regions of interactions are in yellow. It
is also showed details (interacting residues in yellow) and
scheme of interactions between residues in the active site of
GST and the 8-MOP. GSH is in Green. (B) The same for the
inhibitor NBDHEX.
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was visualized in the chromatogram. The absorption spectrum
and chromatographic profiles were the same even after 30 days
incubation (data not shown). Therefore, these data support the
idea that 8-MOP-SG is not formed or it is formed in a very low
extent.
8-MOP EFFICIENTLY INTERACTWITH THE ACTIVE SITE OF THE ENZYME
In silico data strongly suggest an efficient GST-π activity inhi-
bition by 8-MOP that binds to the active site of the enzyme.
The score obtained with Auto Dock Vina as well as the cal-
culations of binding energy from the MD showed good sta-
bility of 8-MOP when compared with NBDHEX (Table 1).
Hydrophobic interactions are made by 8-MOP coumarin core
with residues Phe-8 and Tyr-108. Moreover, it is clear that the
geometric position of 8-MOP inside the active site prevents the
8-MOP-SG formation (Figure 3A). In addition, 8-MOP makes
another important interaction with Trp-38 and forms hydrogen
bonds with Tyr-7 and Leu-52. These two last residues appar-
ently do not directly interact with the NBDHEX. However,
the benzoxadiazole ring of this inhibitor makes the same
hydrophobic interactions with residues Phe-8 and Tyr-108
observed in 8-MOP/GST interactions (Figure 3B). The redock-
ing of the inhibitor NBDHEX in the GSTP1-1 by AutoDock
Vina presented a Root Mean Square Deviation (RMSD) of
1.99 Å from the respective crystal structure (Supplementary
Figure S3A), which is an acceptable deviation docking value.
Furthermore, RMSD vs. time graphics (Supplementary Figures
S3B,C) showed less pronounced variation for the 8-MOP com-
plex, which could indicate an effective stabilization of the system
by 8-MOP.
8-MOP INHIBITS GST FROM TUMOR CELLS AND IS NOT SUBSTRATE
FOR OTHER ISOFORMS OF GST
GST activity in GST-π positive tumor cells (Figure 4A) was
investigated. Km and Vmax calculation could not be performed
since there was not only one isoform of GST in the lysate.
Then, data were analyzed by non-linear regression (R2 = 0.9770)
(Figure 4B). Substrate concentrations greater than 0.5mM sat-
urated the amount of enzyme present in the volume of lysate
used (0.15mL), and saturating conditions (substrate at 1mM)
were used to investigate GST activity inhibition by 8-MOP,
which showed a concentration-dependent pattern (Figure 4C).
Additionally, treatment with 0.05mMCDNB for 15min depleted
intracellular reduced GSH, as expected, but 8-MOP did not pro-
mote GSH depletion (Figure 4D), even at 0.4mM (data not
shown), giving support to our hypothesis that 8-MOP does not
conjugate with GSH. The addition of protein extract from tumor
cells did not also change the spectrum of 8-MOP/GSH solution
(data not shown).
8-MOP SENSITIZES GLIOBLASTOMA CELLS TO DRUGS AND PRESENTS
INTRINSIC ANTITUMOR EFFECT
To investigate evidences of the chemosensitizer action of 8-MOP,
cells from human glioblastoma (GL-15) pre-treated with a
sub-toxic concentration of 8-MOP or vehicle (Figure 5A) were
exposed to chemotherapeutic agents. High concentrations of
temozolomide lead to decreases of cell viability greater than 15%
(Figure 5B) in these cells those are totally resistant to this agent
(Supplementary Figure S4). 8-MOP also increased susceptibil-
ity to etoposide (Figure 5C), which is a recognized substrate for
GST-π. The effects, accessed byMTT assay, were clearly visualized
FIGURE 4 | (A) GL-15 cells labeled positively to GST-π. (B) Conjugation
reaction between CDNB and GSH under increasing concentrations catalyzed
by GST in the cytosolic protein extract of GL-15 cells, followed until the
maximum rate was attained. Line represents non-linear regression
(R2 = 0.9770) of the data. (C) Concentration-dependent inhibition of GST by
8-MOP under maximum rate conditions (1mM CDNB). Data did not present
normal distribution and were analyzed by Kruskal-Wallis non-parametric test
(excluding the first group without DMSO) followed by Dunn’s Multiple
Comparison test ∗p < 0.05 and ∗∗p < 0.01 compared to the control group
(1% DMSO, without 8-MOP). (D) Intracellular GSH assessed by MCB assay.
GSH was present in control conditions and was depleted by CDNB after
30min exposure, but not by 8-MOP.
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by phase contrast microscopy that shows reduction of cellular-
ity and morphological changes promoted by the associations
(Figure 5D). Besides chemosensitizing activity, 8-MOP presented
direct and selective in vitro antitumor effect. It promoted signif-
icant reduction of cell viability in tumor cells, but rat astrocytes
used as normal cells control were not affected to the same extent
(Figure 6A). Microscopic findings suggest that 8-MOP promotes
apoptosis in GL-15 cells (Figures 6B,C). A low concentration of
this drug was also effective for reducing cell proliferation accessed
by trypan blue assay after 10 days exposition (Figure 6D). No
apoptotic signals were found in this experimental design.
DISCUSSION
The overexpression of GSTs in many kinds of tumors encourages
studies with agents able to promote down regulation of these enz-
imes (Zhao et al., 2011), GST-actived pro-drugs aiming selective
action (Pezzola et al., 2010; Johansson et al., 2011; Kogias et al.,
2011) and GSTs inhibitors aiming overpass drug resistance (Cui
et al., 2008; Tentori et al., 2011). However, nowadays, there is no
GST-based approach consistent enough to be adopted as clini-
cal adjuvant therapy. Ethacrynic acid was the first GST inhibitor,
acting as substrate of some isoenzymes of GST, it was utilized to
sensitize cancer cells to the cytotoxic effect of alkylating agents.
However, a number of substantial side effects such as a marked
diuresis have discouraged the use of this molecule in clinical prac-
tice (Quesada-Soriano et al., 2011). In this work, we presented
8-methoxypsoralen (8-MOP) as a promising GST-π inhibitor;
it is a known drug that has been orally and topically used for
decades in the treatment of skin disease like psoriasis and eczema
(Tzaneva et al., 2009).
8-MOP concentration-dependently reduced human GST-π
activity in vitro and also decreased total GST activity in cytoso-
lic extract of human glioblastoma cells. To access the mech-
anism of action, enzyme kinetic assays were performed and
showed a competitive pattern of inhibition with 8-MOP occupy-
ing the hydrophobic binding site (H-site) of the enzyme, keeping
FIGURE 5 | (A) MTT assay data showing that treatment with vehicle and
8-MOP did not change cell viability. (B) GL-15 cells become more sensible
to high concentrations of temozolomide (TMZ) after treatment with 8-MOP,
that significantly reduced viability (MTT assay) of 0.6 and 1mM TZM
treated cells in 17.4% and 16%, respectively. (C) 8-MOP also acted as
chemosensitizer for etoposide, what was statistically significant at 0.001
and 0.1mM. DMSO was kept at 0.05% and 8-MOP at 0.05mM in these
experiments. ∗p < 0.05 and ∗∗p < 0.01. #p < 0.01 compared to group
treated with 8-MOP alone in the experiment with TMZ (Two-way ANOVA
and Bonferroni post-test). Values are means (±s.e.m.). (D) The pictures
show reduction of cellularity and morphological changes promoted by the
associations.
Frontiers in Cellular Neuroscience www.frontiersin.org September 2014 | Volume 8 | Article 308 | 7
de Oliveira et al. 8-MOP inhibits GSTP1-1
FIGURE 6 | (A) Decrease of 21.5% (± 1.9), 29.4% (± 1.4) and 33.4% (± 1.8)
on GL-15 viability after 48 h treatment with 8-MOP at increasing
concentrations (gray bars). Normal cells (white bars) were less affected
(decrease of 17.2% (±5.3) only at maximal concentration). Data are from
MTT assay. Values are means (±s.e.m.). ∗p < 0.01 (One-way ANOVA and
Dunnett’s Multiple Comparison post-test, data from each cell type were
statistically analyzed separately). 0.05% DMSO was present in all groups.
(B) Cell blebbing visualized by phase contrast microscopy and (C)
condensed/fragmented Hoechst 33258 stained nuclei of GL-15. These
findings are suggestive of apoptosis. No morphological evidences of
apoptosis were found among treated astrocytes. (D) Reduced cell
proliferation (evaluated by trypan blue exclusion assay) in GL-15 cells after
long-term exposure to low dose of 8-MOP (10 days, 0.02mM). The number
of cells increased 380% (320,470) in control conditions against 270%
(235,315) in 8-MOP treated group. Values are median (25% percentile, 75%
percentile). Astrocytes were not affected at all. ∗p < 0.05 (Mann Whitney
non-parametric test).
the glutathione binding site (G-site) free. Since inhibition is
competitive, 8-MOP could simply act as a substrate. However,
spectrophotometric and chromatographic analyses showed no
formation of the 8-MOP/GSH conjugate. Additionally, in silico
tests showed that 8-MOP alone interacts with the active site more
favorably than the inhibitor NBDHEX.
Finally, the results from experiment with monochlorobimane
(MCB) suggest that 8-MOP does not act as substrate of GST from
any class, since no GSH depletion occurred at all. Whereas con-
jugation of MCB with GSH is catalyzed by many cytosolic GSTs
(Eklund et al., 2002), the MCB assay also reflects the GST activ-
ity (Ublacker et al., 1991), and then the results also confirm the
reversible nature of the inhibition (since after washing it is possi-
ble to visualize fluorescence) what suggests that 8-MOP does not
inhibit all cytosolic GSTs, presenting any selectivity.
The NBDHEX is a promising non-GSH peptidomimetic
GST-π inhibitor (Ricci et al., 2005) that increased temozolomide
efficacy in an in vivo model of malignant melanoma (Tentori
et al., 2011) and were also effective in overcoming drug resistance
in osteosarcoma cell lines (Wang et al., 2007). 8-MOP is a low
molecular weight hydrophobic compound that easily crosses the
cell membrane; it is also a non-peptidomimetic GST inhibitor,
characteristics that made NBDHEX a promising new therapeutic
possibility. Docking simulations suggested that 8-MOP interact
with active site of GST-π better than NBDHEX. In fact, both, the
free form of 8-MOP and the GSH conjugated form had better
values of binding energy than NBDHEX. Important hydrophobic
interactions made by the benzoxadiazole ring of the NBDHEX
with residues Phe-08 and Tyr-108 can also be observed with the
8-MOP coumarin core. These residues are essential for the activ-
ity of two other inhibitors: clorambutil (Parker et al., 2008) and
ethacrynic acid (Oakley et al., 1997). The 8-MOP also realizes
important interactions with Trp-38, Tyr-7, and Leu-52. These
residues apparently don’t interact with the NBDHEX, as well as
the two others inhibitors cited, clorambutil and ethacrynic acid.
Furthermore, 8-MOP is structurally simple, what facilitates its
synthesis.
Another advantage of 8-MOP is the possibility of short-
term clinical using. There are a number of clinical trials with
8-MOP, that is already clinically used (Berroeta et al., 2010),
and its toxicity in humans is well known (Sehgal, 1975). Also,
many neurological effects of 8-MOP, as insomnia, headache and
dysosmia (Vernassière et al., 2006) suggest that this substance
is able to cross the blood-brain barrier. However, it is impor-
tant to consider that some GST genes present polymorphism,
including GSTP1 gene for which three variants (hGSTP1∗A,
hGSTP1∗B, and hGSTP1∗C) were described. The hGSTP1∗C
variant being expressed at a higher frequency in gliomas than
in normal cells (Kilburn et al., 2010; Backos et al., 2012); this
variant contains an A-to-G transition, causing an isoleucine-to-
valine change and a C-to-T transition, resulting in an Ala114-
Val114 (A114V) substitution. These transitions have impact in
the catalytic activity of the enzyme (Lang et al., 2012), and
then, 8-MOP could act differently in it. Another indication of
the influence of GST variant on 8-MOP activity is that GST
polymorphism influences the outcome of therapy with 8-MOP,
although plasma concentrations of the drug have not been
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associated with different genotypes of the enzyme (Ibbotson
et al., 2012). A future clinical use of 8-MOP as GST inhibitor
must take these information into account. Associations between
GSTP1 polymorphism (and activity) and other pathological con-
ditions, mainly neurodegenerative diseases, like multiple scle-
rosis (Alexoudi et al., 2014), Parkinson’s disease (Longo et al.,
2013) and essential tremor (Martínez et al., 2008), could sug-
gest side effects of inhibition of GST activity, but, in the other
hand, they also increase the potential therapeutic scope of this
prototype.
Co-expression of GST-π and the efflux pump MRP1 (multi-
drug resistance protein 1) was associated with resistance to etopo-
side (Depeille et al., 2005). 8-MOP was tested as chemosensitizer
in cultures of human glioblastoma cells when co-administered
with this drug and the standard agent TMZ, and it was effec-
tive for both, what is probable due to its GST-π inhibitory
action. 8-MOP also showed intrinsic antitumor effect against
these cells. Indeed, GST-π is also involved in the regulation of
apoptosis through the inhibition of the c-Jun-N-terminal kinase
(JNK) signaling pathway. The enzyme binds to JNK prevent-
ing its phosphorylation and, hence, blocking its kinase activ-
ity (Tew and Townsend, 2011); the oligomerization of GST-π
promotes the uncoupling and releases JNK, that can act on
apoptotic pathway and amplify cell death stimuli (Laborde,
2010). That is the probable explanation for resistance toward
drugs which are not substrates for GSTs in tumor cells those
overexpress this enzyme (Tew and Townsend, 2011). In fact,
intrinsic proapoptotic activity was also described to other GST
inhibitors (Turella et al., 2005; Tregno et al., 2009). However,
it is important take into account that the oligomerization of
GST-π also influences (negatively) the catalytic activity of the
enzyme (Bernardini et al., 2000) and several GST inhibitors,
including ethacrynic acid, can promote this oligomerization
(Sánchez-Gómez et al., 2013). Thus, the antitumor effect and
probable apoptosis promoting activity of 8-MOP is now under
investigation.
In conclusion, we have shown new application for a well-
established drug. 8-MOP can represent a molecule of a novel class
of GST inhibitors. The therapeutic potential of these inhibitors
is not restricted to cancer treatment, they could also have appli-
cation in treatment of infectious diseases since GST activity has
been reported inmany pathogenic parasites (Mahajan and Atkins,
2005). Ours results also have implications for current treatment
using 8-MOP, like PUVA (psoralen plus ultraviolet A) therapy,
and neurodegenerative diseases involving GSH depletion or any
pathologic condition in which GST has an important role.
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